On the 30 March 2016, the Board of Directors of AddLife AB (publ) (”AddLife”) resolved on the terms and conditions of the share issue with preferential rights for existing shareholders in AddLife (the “Issue”). The terms and conditions were published through a press release the same day. The decision regarding the terms and conditions of the Issue, as well as the acquisitions of V-Tech AB and Esthe-Tech AB and that AddLife signed an agreement to represent Leica Biosystems in Sweden and Denmark, which have been published through press releases on 17 March 2016 and 4 April 2016, respectively, required that a prospectus supplement was prepared. The prospectus supplement has now been approved and registered by the Swedish Financial Supervisory Authority. The prospectus supplement is available on the company’s website, www.add.life, as well as on Handelsbanken’s website, www.handelsbanken.se/investeringserbjudande.
Handelsbanken Capital Markets acts as financial adviser and Advokatfirman Delphi acts as legal adviser in connection with the Issue.
Stockholm, April 5, 2016
AddLife AB (publ)
For further information, please contact:
Kristina Willgård, CEO, [email protected], +46 70 510 12 23
Martin Almgren, CFO, [email protected], +46 70 228 15 45
The information in this press release shall not constitute an offer to acquire, subscribe for or otherwise trade in shares or other securities in AddLife. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Invitation to the persons concerned to subscribe for shares is only made through the prospectus which AddLife published on 15 March 2016.
The information in this press release may not be released, published or distributed, directly or indirectly, in or into the United States (including its territories and provinces, every state in the United States and the District of Columbia), Canada, Australia, Japan, Hong Kong, New Zeeland, Switzerland, Singapore, South Africa or any other jurisdiction in which such action is subject to legal restrictions or would require other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws.
No shares or other securities have or will be registered under the United States Securities Act of 1933 or the securities legislation in any state or other jurisdiction in the United States and may not be offered, subscribed, sold or transferred, directly or indirectly, within the United States.
AddLife is an independent player in the Life Science sector, offering high-quality products, services and advice to the private and public sectors, above all in the Nordic region. AddLife has about 425 employees in some 25 subsidiaries that operate under their own brands. The Group has annual sales of about SEK 1.7 billion. Addlife’s shares are listed on Nasdaq Stockholm.
This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act and/or the regulations of Nasdaq Stockholm. The information was provided for publication at 17:15 PM on April 5 2016.